165 related articles for article (PubMed ID: 30209389)
1. STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas.
Pan YR; Chen CC; Chan YT; Wang HJ; Chien FT; Chen YL; Liu JL; Yang MH
Nat Commun; 2018 Sep; 9(1):3696. PubMed ID: 30209389
[TBL] [Abstract][Full Text] [Related]
2. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
[TBL] [Abstract][Full Text] [Related]
4. Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Lu L; Zhu F; Zhang M; Li Y; Drennan AC; Kimpara S; Rumball I; Selzer C; Cameron H; Kellicut A; Kelm A; Wang F; Waldmann TA; Rui L
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E498-E505. PubMed ID: 29295936
[TBL] [Abstract][Full Text] [Related]
5. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
[TBL] [Abstract][Full Text] [Related]
6. STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Assumpção ALFV; Jark PC; Hong CC; Lu Z; Ruetten HM; Heaton CM; Pinkerton ME; Pan X
J Vet Intern Med; 2018 Jan; 32(1):361-369. PubMed ID: 29119628
[TBL] [Abstract][Full Text] [Related]
7. STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.
Hardee J; Ouyang Z; Zhang Y; Kundaje A; Lacroute P; Snyder M
G3 (Bethesda); 2013 Dec; 3(12):2173-85. PubMed ID: 24142927
[TBL] [Abstract][Full Text] [Related]
8. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.
Zhao T; Ren H; Wang X; Liu P; Yan F; Jiang W; Li Y; Li J; Gribben JG; Jia L; Hao J
Oncotarget; 2015 Sep; 6(29):27816-31. PubMed ID: 26315113
[TBL] [Abstract][Full Text] [Related]
10. A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
Hu G; Witzig TE; Gupta M
PLoS One; 2013; 8(7):e67851. PubMed ID: 23861822
[TBL] [Abstract][Full Text] [Related]
11. Expression and significance of leptin receptor, p-STAT3 and p-AKT in diffuse large B-cell lymphoma.
Lin S; YuJun L; XiaoMing X; WenWen R
Acta Histochem; 2014 Jan; 116(1):126-30. PubMed ID: 24054064
[TBL] [Abstract][Full Text] [Related]
12. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
13. Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.
Högfeldt T; Johnsson P; Grandér D; Bahnassy AA; Porwit A; Eid S; Österborg A; Zekri AR; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Leuk Lymphoma; 2014 May; 55(5):1158-65. PubMed ID: 23841503
[TBL] [Abstract][Full Text] [Related]
14. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
15. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
[TBL] [Abstract][Full Text] [Related]
16. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma.
Scuto A; Kujawski M; Kowolik C; Krymskaya L; Wang L; Weiss LM; Digiusto D; Yu H; Forman S; Jove R
Cancer Res; 2011 May; 71(9):3182-8. PubMed ID: 21521803
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
18. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
[TBL] [Abstract][Full Text] [Related]
19. STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma.
Xiao S; Fan C; Ma J; Xue H; Xu L
Acta Haematol; 2022; 145(4):371-383. PubMed ID: 34915482
[TBL] [Abstract][Full Text] [Related]
20. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.
Zhong W; Zhu Z; Xu X; Zhang H; Xiong H; Li Q; Wei Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):73. PubMed ID: 30755239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
